• 1
    Green SM, Martinez-Rumayor A, Gregory SA, et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 2008;168:741748.
  • 2
    Worster A, Balion CM, Hill SA, et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: A systematic review. Clin Biochem 2008;41:250259.
  • 3
    Januzzi JL, Chen-Tournous AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101:2938.
  • 4
    Ray P, Delerme S, Jourdain P, Chenevier-Gobeaux C. Differential diagnosis of acute dyspnea: The value of B natriuretic peptides in the emergency department. Q J Med 2008;101:831843.
  • 5
    Connolly DJ, Soares Magalhaes RJ, Fuentes VL, et al. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 2009;11:541550.
  • 6
    Fox PR, Oyama MA, Reynolds CA, et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol 2009;11:551561.
  • 7
    Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:15811588.
  • 8
    Connolly DJ, Magalhaes RJ, Syme HM, et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008;22:96105.
  • 9
    Fox PR, Rush JE, Reynolds CA, et al. Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-proBNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats. J Vet Intern Med 2011;25:10101016.
  • 10
    Robaei D, Koe L, Bais R, et al. Effect of NT-proBNP testing on diagnostic certainty in patients admitted to the emergency department with possible heart failure. Ann Clin Biochem 2011;48:212217.
  • 11
    Schmidt MK, Reynolds CA, Estrada AH, et al. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: A pilot study. J Vet Cardiol 2009;11:581586.
  • 12
    Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 2003;42:17931800.
  • 13
    Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NT-proBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537541.
  • 14
    Lister AL, Buchanan JW. Vertebral scale system to measure heart size in radiographs of cats. J Am Vet Med Assoc 2000;216:210214.
  • 15
    McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from breathing not properly (BNP) multinational study. Circulation 2002;106:416422.
  • 16
    Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF Study. Circulation 2007;115:31033110.
  • 17
    Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647654.
  • 18
    Tang WH, Francis GS, Morrow DA, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Clin Chem 2008;41:210221.
  • 19
    Lam LL, Cameron PA, Schneider HG, et al. Meta-analysis: Effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med 2010;153:728735.